Ormeloxifene for Fibroadenosis, Fibroadenoma and Associated Mastalgia: A Critical Narrative Review of Mechanistic Rationale, Clinical Efficacy and Safety
Lavu Jayanth *
AIIMS Mangalagiri, India.
Dasari Lalith
Gandhi Medical College, Secunderabad, India.
*Author to whom correspondence should be addressed.
Abstract
Benign breast disorders frequently present with mastalgia, diffuse nodularity or a discrete fibroadenoma, but these phenotypes differ biologically and should not be treated as interchangeable therapeutic targets. Ormeloxifene (centchroman) is a non-steroidal selective oestrogen receptor modulator developed in India and subsequently investigated as a medical treatment for benign breast symptoms and fibroadenoma regression. This critical narrative review evaluates the biological rationale, clinical effectiveness, safety and practical positioning of ormeloxifene for fibroadenosis or fibrocystic-type nodularity, fibroadenoma and associated mastalgia. Literature published from 1974 to 12 June 2026 was identified through live searches of PubMed, Europe PMC, Crossref and OpenAlex, supplemented by citation searching and verification against authoritative bibliographic records. Early uncontrolled studies and several active-comparator trials reported substantial reductions in breast pain, nodularity and fibroadenoma size. Their interpretation is constrained by small samples, open-label designs, short follow-up, heterogeneous dosing, imprecise diagnostic labels and the natural fluctuation of both mastalgia and fibroadenoma. Later placebo-controlled evidence substantially weakens the case for routine use. In mastalgia, a three-arm randomised study found high improvement rates in both ormeloxifene and placebo groups, whereas more recent comparison with tamoxifen suggests similar medium-term symptom control rather than clear superiority. For fibroadenoma, a 2024 double-blind placebo-controlled trial showed no improvement in complete regression and more adverse events, while a later randomised trial reported a favourable responder subgroup despite a non-significant primary between-group volume comparison. A 2025 meta-analysis of randomised trials found no significant efficacy advantage for fibroadenoma regression and a higher rate of adverse effects. Menstrual disturbance is the most consistent toxicity signal; ovarian cysts and dizziness have also been reported. The current evidence therefore supports diagnostic precision and stepped symptom management rather than routine ormeloxifene prescribing, with any use for refractory mastalgia requiring careful selection, counselling and monitoring. Evidence is insufficient to support ormeloxifene as standard pharmacological therapy for fibroadenoma regression.
Keywords: Centchroman, benign breast disease, breast pain, breast nodularity, fibrocystic change, selective oestrogen receptor modulator, fibroadenoma